Thus, different compounds are under investigation, including the SMO inhibitor vismodegib in SMO-mutant tumors, the AKT inhibitor capivasertib (AZD5363) for AKT/PIK3CA-mutant tumors, the CDK inhibitor abemaciclib for NF2 or CDK-mutant tumors, and the FAK inhibitor GSK2256098 for SMO/PTCH1-mutant and NF2-mutant meningiomas, respectively (NCT02523014). Here, PTCH1 is linked to meningioma.